UCB SA (OTCMKTS:UCBJF – Get Free Report) shares gapped up prior to trading on Thursday. The stock had previously closed at $314.48, but opened at $333.39. UCB shares last traded at $333.39, with a volume of 46 shares.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Wednesday, October 21st. Jefferies Financial Group raised shares of UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, UCB has a consensus rating of “Moderate Buy”.
Get Our Latest Stock Report on UCB
UCB Stock Up 3.3%
The stock has a 50-day simple moving average of $263.88 and a 200-day simple moving average of $286.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.
About UCB
UCB is a Belgian biopharmaceutical company founded in 1928 and headquartered in Brussels. It discovers, develops and commercializes medicines, with a focus on neurological and immunological conditions. Its products include treatments for epilepsy, such as Keppra, Briviact and Nayzilam, as well as medicines for inflammatory diseases, including Cimzia and Bimzelx. UCB also develops therapies for other serious conditions, including myasthenia gravis. The company serves patients and healthcare providers in markets around the world.
Further Reading
- Five stocks we like better than UCB
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
